Literature DB >> 25086175

Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion.

Robert L Ferris1, Binfeng Lu2, Lawrence P Kane3.   

Abstract

T cell exhaustion is thought to be a natural mechanism for limiting immune pathology, although it may be desirable to circumvent this mechanism to help eliminate viral reservoirs or tumors. Although there are no definitive markers, a fingerprint for exhausted T cells has been described that includes the transmembrane proteins PD-1, LAG3, and Tim-3. However, apart from the recruitment of tyrosine phosphatases to PD-1, little is known about the biochemical mechanisms by which these proteins contribute to the development or maintenance of exhaustion. Tim-3 contains no known motifs for the recruitment of inhibitory phosphatases, but it may actually increase signaling downstream of TCR/CD3, at least under acute conditions. Other studies showed that T cell exhaustion results from chronic stimulation that extends the effector phase of T cell activation, at the expense of T cell memory. We suggest that Tim-3 may contribute to T cell exhaustion by enhancing TCR-signaling pathways.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25086175      PMCID: PMC4120324          DOI: 10.4049/jimmunol.1400557

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

Authors:  Ganesh Suntharalingam; Meghan R Perry; Stephen Ward; Stephen J Brett; Andrew Castello-Cortes; Michael D Brunner; Nicki Panoskaltsis
Journal:  N Engl J Med       Date:  2006-08-14       Impact factor: 91.245

2.  Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity.

Authors:  Rachel H McMahan; Lucy Golden-Mason; Michael I Nishimura; Brian J McMahon; Michael Kemper; Todd M Allen; David R Gretch; Hugo R Rosen
Journal:  J Clin Invest       Date:  2010-11-15       Impact factor: 14.808

Review 3.  Emerging Tim-3 functions in antimicrobial and tumor immunity.

Authors:  Kaori Sakuishi; Pushpa Jayaraman; Samuel M Behar; Ana C Anderson; Vijay K Kuchroo
Journal:  Trends Immunol       Date:  2011-06-21       Impact factor: 16.687

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin.

Authors:  Rajesh R Rao; Qingsheng Li; Kunle Odunsi; Protul A Shrikant
Journal:  Immunity       Date:  2010-01-07       Impact factor: 31.745

6.  Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.

Authors:  Lucy Golden-Mason; Brent E Palmer; Nasim Kassam; Lisa Townshend-Bulson; Stephen Livingston; Brian J McMahon; Nicole Castelblanco; Vijay Kuchroo; David R Gretch; Hugo R Rosen
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

7.  Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.

Authors:  Carrie L Lucas; Hye Sun Kuehn; Fang Zhao; Julie E Niemela; Elissa K Deenick; Umaimainthan Palendira; Danielle T Avery; Leen Moens; Jennifer L Cannons; Matthew Biancalana; Jennifer Stoddard; Weiming Ouyang; David M Frucht; V Koneti Rao; T Prescott Atkinson; Anahita Agharahimi; Ashleigh A Hussey; Les R Folio; Kenneth N Olivier; Thomas A Fleisher; Stefania Pittaluga; Steven M Holland; Jeffrey I Cohen; Joao B Oliveira; Stuart G Tangye; Pamela L Schwartzberg; Michael J Lenardo; Gulbu Uzel
Journal:  Nat Immunol       Date:  2013-10-28       Impact factor: 25.606

8.  Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism.

Authors:  Andrew N Macintyre; David Finlay; Gavin Preston; Linda V Sinclair; Caryll M Waugh; Peter Tamas; Carmen Feijoo; Klaus Okkenhaug; Doreen A Cantrell
Journal:  Immunity       Date:  2011-02-03       Impact factor: 31.745

9.  Tim-3 negatively regulates IL-12 expression by monocytes in HCV infection.

Authors:  Ying Zhang; Cheng J Ma; Jia M Wang; Xiao J Ji; Xiao Y Wu; Zhan S Jia; Jonathan P Moorman; Zhi Q Yao
Journal:  PLoS One       Date:  2011-05-26       Impact factor: 3.240

Review 10.  Tim-3: an activation marker and activation limiter of innate immune cells.

Authors:  Gencheng Han; Guojiang Chen; Beifen Shen; Yan Li
Journal:  Front Immunol       Date:  2013-12-10       Impact factor: 7.561

View more
  55 in total

Review 1.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

2.  Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients.

Authors:  Hyun-Bae Jie; Raghvendra M Srivastava; Athanassios Argiris; Julie E Bauman; Lawrence P Kane; Robert L Ferris
Journal:  Cancer Immunol Res       Date:  2017-04-13       Impact factor: 11.151

3.  Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.

Authors:  Gulidanna Shayan; Raghvendra Srivastava; Jing Li; Nicole Schmitt; Lawrence P Kane; Robert L Ferris
Journal:  Oncoimmunology       Date:  2016-12-23       Impact factor: 8.110

4.  Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk.

Authors:  Jing Li; Gulidanna Shayan; Lyndsay Avery; Hyun-Bae Jie; Neil Gildener-Leapman; Nicole Schmitt; Bin Feng Lu; Lawrence P Kane; Robert L Ferris
Journal:  Oncoimmunology       Date:  2016-09-22       Impact factor: 8.110

Review 5.  Immunomodulation: checkpoint blockade etc.

Authors:  William T Curry; Michael Lim
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 6.  T cell exhaustion during persistent viral infections.

Authors:  Shannon M Kahan; E John Wherry; Allan J Zajac
Journal:  Virology       Date:  2015-01-22       Impact factor: 3.616

Review 7.  Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.

Authors:  Dirk Schadendorf; Paul Nghiem; Shailender Bhatia; Axel Hauschild; Philippe Saiag; Lisa Mahnke; Subramanian Hariharan; Howard L Kaufman
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

8.  TIM-3 Engagement Promotes Effector Memory T Cell Differentiation of Human Antigen-Specific CD8 T Cells by Activating mTORC1.

Authors:  Nina Chi Sabins; Olesya Chornoguz; Karen Leander; Fred Kaplan; Richard Carter; Michelle Kinder; Kurtis Bachman; Raluca Verona; Shixue Shen; Vipul Bhargava; Sandra Santulli-Marotto
Journal:  J Immunol       Date:  2017-11-10       Impact factor: 5.422

9.  Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion.

Authors:  Lyndsay Avery; Jessica Filderman; Andrea L Szymczak-Workman; Lawrence P Kane
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-20       Impact factor: 11.205

Review 10.  Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions.

Authors:  Mark N Polizzotto; Grace Chen; Randall L Tressler; Catherine Godfrey
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.